Universal AAV Enhancer For Improved Viral Titers, Quality, And Reduced Production Costs

AAV therapies require high quality and high titers of viral genomes per dosage, prompting the need for a more efficient AAV manufacturing method to reduce overall costs. The RevIT enhancer was created in response to this need with the potential to increase higher genome titers 2-4X in a range of suspension HEK 293 subtypes and cell culture media. Additional features allow you the flexibility to produce multiple AAV serotypes and, when paired with Mirus Bio's TransIT-VirusGen Transfection Reagent, enable complex stability in AAV manufacturing. Explore all the ways RevIT enhances your AAV production.